Open Access

Expression and clinical significance of FXYD3 in endometrial cancer

  • Authors:
    • Yifei Li
    • Xia Zhang
    • Shuwen Xu
    • Jing Ge
    • Jing Liu
    • Lin Li
    • Guiying  Fang
    • Yali Meng
    • Hongzhen Zhang
    • Xiaofeng Sun
  • View Affiliations

  • Published online on: May 23, 2014     https://doi.org/10.3892/ol.2014.2170
  • Pages: 517-522
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

FXYD3 expression is upregulated in numerous cancer cell types. The present study compared the FXDY3 expression in normal endometrium, premalignant lesion and endometrial cancer tissue samples, and investigated the correlation between FXDY3 expression and clinicopathological features. FXYD3 expression was analyzed by streptavidin‑peroxidase immunohistochemistry in 21 normal endometrial tissue samples, 18 atypical endometrial hyperplasia samples and 50 tissues obtained from patients diagnosed with endometrial cancer. The percentage of FXYD3‑positive cell expression in the normal endometrium, atypical hyperplasia and endometrial cancer tissues samples was 0, 22, and 26%, respectively. The differences between the atypical hyperplasia and endometrial cancer groups were statistically significant when compared with the normal group (P=0.007 and P=0.037, respectively). There was no significant difference between the atypical hyperplasia and endometrial cancer groups. The percentage of FXYD3‑positive cells correlated with the fertility frequency (P<0.05). In conclusion, FXYD3 is a potential biomarker for endometrial cancer, and its upregulation may be an early event in endometrial carcinoma progression. In addition, FXYD3 expression in endometrial carcinoma correlates with fertility frequency.
View Figures
View References

Related Articles

Journal Cover

August-2014
Volume 8 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Y, Zhang X, Xu S, Ge J, Liu J, Li L, Fang G, Meng Y, Zhang H, Sun X, Sun X, et al: Expression and clinical significance of FXYD3 in endometrial cancer. Oncol Lett 8: 517-522, 2014
APA
Li, Y., Zhang, X., Xu, S., Ge, J., Liu, J., Li, L. ... Sun, X. (2014). Expression and clinical significance of FXYD3 in endometrial cancer. Oncology Letters, 8, 517-522. https://doi.org/10.3892/ol.2014.2170
MLA
Li, Y., Zhang, X., Xu, S., Ge, J., Liu, J., Li, L., Fang, G., Meng, Y., Zhang, H., Sun, X."Expression and clinical significance of FXYD3 in endometrial cancer". Oncology Letters 8.2 (2014): 517-522.
Chicago
Li, Y., Zhang, X., Xu, S., Ge, J., Liu, J., Li, L., Fang, G., Meng, Y., Zhang, H., Sun, X."Expression and clinical significance of FXYD3 in endometrial cancer". Oncology Letters 8, no. 2 (2014): 517-522. https://doi.org/10.3892/ol.2014.2170